It was therefore necessary to grow the yeast cells in our fermenters to high densities ... chemical step by modifying the ...

Autolus Therapeutics ( (AUTL) ) has provided an announcement. Autolus Therapeutics has achieved a pivotal milestone with the FDA’s ...

Producing herbal medicines on an industrial scale is challenging. However, a team of bioengineers from Kobe University has ...

Herbal medicine is difficult to produce on an industrial scale. A team of Kobe University bioengineers manipulated the ...

That was among the many special moments for 11-year-old Cooper Trueblood at the Washington Capitals’ annual Hockey Fights ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

The therapy was cleared to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) after showing complete remission in 63% of efficacy evaluable patients during Autolus’ ...

The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...

Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...

The investigators added that inflammation and demyelination were reduced, while axonal density oligodendrocytes, ...

Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...